Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propofol–Remifentanil vs Propofol–Hydralazine for blood loss during dacryocystorhinostomy
IRCT20171030037093N30Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Feb 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial comparing Propofol + Remifentanil with Propofol + Hydralazine (2 arms). Primary endpoint: Intraoperative blood loss volume. Started Feb 2020; status: completed.
02
Drugs
propofolremifentanilhydralazine
Beyond the preview
Go deeper on IRCT20171030037093N30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20171030037093N30.